Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts

Digestive Diseases and Sciences

Volumn 53, Issue 5, 2008, Pages 1206-1210

  Huang, Wei ^a   Wu, Yun Lin ^a   Zhong, Jie ^a   Jiang, Feng Xiang ^a   Tian, Xiang Long ^a   Yu, Li Fen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Angiogenesis; Angiotensin II type1 receptor antagonist; Gastric cancer

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR GROWTH; UPREGULATION; XENOGRAFT;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; STATISTICS, NONPARAMETRIC; STOMACH NEOPLASMS; TETRAZOLES; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 41949114891     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-0009-9     Document Type: Article

References (29)

1. Sun XD, Mu R, Zhou YS, Dai XD, Zhang SW, Huangfu XM, Sun J, Li LD, Lu FZ, Qiao YL (2004) Analysis of mortality rate of stomach cancer and its trend in 20 years in China. Zhonghua Zhong Liu Za Zhi 26:4-9
2. Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16:293-299
3. Escobar E, Rodriguez-Reyna TS, Arrieta O et al (2004) Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 4:385-399
4. Smith GR, Missailidis S (2004) Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm 1:1-12
5. Ino K, Shibata K, Kajiyama H et al (2006) Manipulating the angiotensin system-new approaches to the treatment of solid tumors. Expert Opin Biol Ther 6:243-255
6. Volpert O et al (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671-679
7. Hii S et al (1998) Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 77:880-883
8. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H (2001) The angiotensin- I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7:1073-1078
9. Prontera C et al (1999) Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 81:761-766
10. Dinh DT, Frauman AG, Somers GR et al (2002) Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT (1) receptor expression in benign prostatic hyperplasia. J Pathol 196:213-219
11. Ino K, Shibata K, Kajiyama H et al (2006) Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumor angiogenesis and patient survival. Br J Cancer 94:552-560
12. Lam KY, Leung PS (2002) Regulation and expression of a renin-angiotensin system in human pancreas and pancreatic endocrine tumors. Eur J Endocrinol 146:567-572
13. Takeda H, Kondo S (2001) Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 158:1633-1637
14. Egami K, Murohara T, Shimada T et al (2003) Role of host angiotensin II type 1receptor in tumor angiogenesis and growth. J Clin Invest 112:67-75
15. Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, Schirner M (2003) Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 14:2061-2067
16. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M (2005) Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26:271-279
17. Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43:175-203
18. Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505-515
19. Kondo K, Muramatsu M, Okamoto Y et al (2006) Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. J Surg Oncol 93:36-42
20. Muramatsu M, Katada J, Hayashi I, Majima M (2000) Chymase as a proangiogenic factor. J Biol Chem 275:5545-5552
21. Fujimoto Y, Sasaki T, Tsuchida A et al (2001) Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 495:197-200
22. Uemura H, Ishiguro H, Nakaigawa N et al (2003) Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2:1139-1147
23. Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J (2001) AT1 receptor is present in glioma cells its blockage reduces the growth of rat glioma. Br J Cancer 85:1396-1399
24. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294:441-447
25. Miyajima A, Kosaka T, Asano T et al (2002) Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62:4176-4179
26. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai1 M (2006) Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 12:2888-2893
27. Suganuma T, Ino K, Shibata K et al (2005) Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 11:2686-2694
28. Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T, Asano T, Sakamoto M, Okita H, Murai M, Hayakawa M (2007) Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 67:41-49
29. Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H, Kubota Y (2005) Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 10:405-410